Back to today’s briefing

Story perspectives

New Enzyme Class Revealed: Potential for Healthy Aging

10/5/2025

39 6

Summary

Story summary

Researchers at Queen Mary University of London report rapalink-1, a Target of Rapamycin (TOR) inhibitor, slows yeast growth.
The TOR pathway governs growth, metabolism, and aging, influencing cancer and neurodegeneration.
The study identifies agmatinases as a new enzyme class that modulates TOR via metabolic feedback.
Findings suggest combining TOR-targeting drugs with dietary and microbial interventions to promote healthy aging.

1 of 1

Story summary

Researchers at Queen Mary University of London report rapalink-1, a Target of Rapamycin (TOR) inhibitor, slows yeast growth.
The TOR pathway governs growth, metabolism, and aging, influencing cancer and neurodegeneration.
The study identifies agmatinases as a new enzyme class that modulates TOR via metabolic feedback.
Findings suggest combining TOR-targeting drugs with dietary and microbial interventions to promote healthy aging.